2021年USPSTF肺癌筛查标准与其他肺癌筛查标准在种族差异方面的比较
该研究纳入912例肺癌患者和1457例对照,比较2021年USPSTF、2013年USPSTF和PLCOm2012三种肺癌筛查标准的敏感性和特异性及种族差异。2021年USPSTF标准使65%肺癌患者符合筛查,高于2013年USPSTF的49%,与PLCOm2012的68%接近;2013年标准下白人患者符合率52%高于非裔美国人42%,此差异在2021年标准和PLCOm2012标准下消失。结论提示2021年USPSTF标准扩大了筛查资格并减少了种族差异。
要点
- 2021年USPSTF标准使65%肺癌患者符合筛查,2013年USPSTF为49%,PLCOm2012为68%。
- 2013年USPSTF标准下白人肺癌患者符合率52%高于非裔美国人42%,存在种族差异。
- 2021年USPSTF和PLCOm2012标准下种族差异消失(白人65% vs 非裔63%;68% vs 67%)。
核心结论
- 本研究提示USPSTF 2021年指南修改改善了早期固定筛查标准,扩大了筛查资格并减少了筛查可及性的种族差异。
研究设计与样本
- 研究纳入912例肺癌患者和1457例无肺癌对照,参与者来自2012年5月15日至2018年3月31日在底特律大都市区开展的INHALE流行病学研究。
- 肺癌患者和对照年龄为21至89岁;从不吸烟的肺癌患者和从不吸烟的对照未纳入分析。
- 统计分析于2020年8月31日至2021年4月13日进行。
主要发现
- 使用2021年USPSTF标准,590例肺癌患者(65%)符合筛查;PLCOm2012标准为619例(68%);2013年USPSTF标准为445例(49%)。
- 使用2013年USPSTF标准,白人肺癌患者符合筛查比例52%(324/625)高于非裔美国人42%(121/287),差异显著。
- 使用2021年USPSTF标准,白人肺癌患者65%(408/625)与非裔美国人63%(182/287)符合筛查,种族差异消失;PLCOm2012标准为白人68%(427/625)vs 非裔67%(192/287)。
- 2013年USPSTF标准排除950例对照(65%),PLCOm2012排除843例(58%),2021年USPSTF排除709例(49%)。
- 2013年USPSTF标准排除白人对照61%(514/838)少于非裔对照70%(436/619);2021年USPSTF标准为白人48%(401/838)vs 非裔50%(308/619);PLCOm2012为白人57%(475/838)vs 非裔60%(368/619)。
关键数值与推荐
- 2021年USPSTF标准:肺癌患者符合筛查65%(590/912),对照排除49%(709/1457)。
- 2013年USPSTF标准:肺癌患者符合筛查49%(445/912),对照排除65%(950/1457)。
- PLCOm2012标准:肺癌患者符合筛查68%(619/912),对照排除58%(843/1457)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In 2021, the US Preventive Services Task Force (USPSTF) broadened its age and smoking pack-year requirement for lung cancer screening. OBJECTIVES: To compare the 2021 USPSTF lung cancer screening criteria with other lung cancer screening criteria and evaluate whether the sensitivity and specificity of these criteria differ by race. DESIGN, SETTING, AND PARTICIPANTS: This study included 912 patients with lung cancer and 1457 controls without lung cancer enrolled in an epidemiology study (INHALE [Inflammation, Health, Ancestry, and Lung Epidemiology]) in the Detroit metropolitan area between May 15, 2012, and March 31, 2018. Patients with lung cancer and controls were 21 to 89 years of age; patients with lung cancer who were never smokers and controls who were never smokers were not included in these analyses. Statistical analysis was performed from August 31, 2020, to April 13, 2021. MAIN OUTCOMES AND MEASURES: The study assessed whether patients with lung cancer and controls would have qualified for lung cancer screening using the 2013 USPSTF, 2021 USPSTF, and 2012 modification of the model from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCOm2012) screening criteria. Sensitivity was defined as the percentage of patients with lung cancer who qualified for screening, while specificity was defined as the percentage of controls who did not qualify for lung cancer screening. RESULTS: Participants included 912 patients with a lung cancer diagnosis (493 women [54%]; mean [SD] age, 63.7 [9.5] years) and 1457 control participants without lung cancer at enrollment (795 women [55%]; mean [SD] age, 60.4 [9.6] years). With the use of 2021 USPSTF criteria, 590 patients with lung cancer (65%) were eligible for screening compared with 619 patients (68%) per the PLCOm2012 criteria and 445 patients (49%) per the 2013 USPSTF criteria. With the use of 2013 USPSTF criteria, significantly more White patients than African American patients with lung cancer (324 of 625 [52%] vs 121 of 287 [42%]) would have been eligible for screening. This racial disparity was absent when using 2021 USPSTF criteria (408 of 625 [65%] White patients vs 182 of 287 [63%] African American patients) and PLCOm2012 criteria (427 of 625 [68%] White patients vs 192 of 287 [67%] African American patients). The 2013 USPSTF criteria excluded 950 control participants (65%), while the PLCOm2012 criteria excluded 843 control participants (58%), and the 2021 USPSTF criteria excluded 709 control participants (49%). The 2013 USPSTF criteria excluded fewer White control participants than African American control participants (514 of 838 [61%] vs 436 of 619 [70%]). This racial disparity is again absent when using 2021 USPSTF criteria (401 of 838 [48%] White patients vs 308 of 619 [50%] African American patients) and PLCOm2012 guidelines (475 of 838 [57%] White patients vs 368 of 619 [60%] African American patients). CONCLUSIONS AND RELEVANCE: This study suggests that the USPSTF 2021 guideline changes improve on earlier, fixed screening criteria for lung cancer, broadening eligibility and reducing the racial disparity in access to screening.
引用
- Pu CY, Lusk CM, Neslund-Dudas C, et al. Comparison Between the 2021 USPSTF Lung Cancer Screening Criteria and Other Lung Cancer Screening Criteria for Racial Disparity in Eligibility. JAMA Oncol. 2022. PMID: 35024781. doi:10.1001/jamaoncol.2021.6720
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。